Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin

British Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2002, Pages 485-491

  Dingemanse, Jasper ^a   Meyerhoff, Carsten ^b   Schadrack, Jan ^c  

^a Jacor Research   (Switzerland)

^b AAI   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Entacapone; Interaction; Parkinson's disease; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

CATECHOL METHYLTRANSFERASE; ENTACAPONE; WARFARIN; ANTICOAGULANT AGENT; CATECHOL DERIVATIVE; ENZYME INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; FATIGUE; FEMALE; GINGIVA BLEEDING; HEADACHE; HUMAN; INTERNATIONAL STANDARD UNIT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PYURIA; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; DRUG ANTAGONISM; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTICOAGULANTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMAN; MALE; MIDDLE AGE; WARFARIN; HUMANS; MIDDLE AGED;

EID: 0035999637     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01587.x     Document Type: Article

References (33)

1. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating parkinsonian patients
2. Parkinson's disease
3. Continuous dopamine-receptor stimulation in early Parkinson's disease
4. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors
5. Catechol-O-methyltransferease inhibitors. Clinical potential in the treatment of Parkinson's disease
6. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease
7. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease
8. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
9. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease
10. Preventing levodopa-induced dyskinesias
11. The rise and fall of tolcapone
12. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
13. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
14. The UK-Irish double-blind study of entacapone in Parkinson's disease
15. Entacapone efficacy in Parkinson's disease
16. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production
17. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat
18. Issues important for rational COMT inhibition
19. Interaction of warfarin with drugs and food
20. Clinically important drug interactions with anticoagulants. An update
21. Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model
22. Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man
23. Lack of interaction between meloxicam and warfarin in healthy volunteers
24. Stereospecific fluorescence high-performance liquid chromatography analysis of (R)- and (S)-warfarin and its metabolites in plasma and urine
25. Lack of pharmacokinetic interaction as an equivalence problem
26. The use of non-parametric methods in the statistical analysis of the two-period changeover design
27. Phenylbutazone-warfarin interaction in man. Further stereochemical and metabolic considerations
28. The warfarin-cimetidine interaction: Stereochemical considerations
29. Stereoselective interaction of omeprazole with warfarin in healthy men
30. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults
31. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
32. Method for studying drug-warfarin interactions
33. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique